Editorial for “a predictive model for irAEs in ESCC patients treated with PD-1 inhibitors based on blood indicators”

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Future Science OA
المؤلفون الرئيسيون:	Yaser Soleimani, Seyedehhoda Khatibmasjedi, Seyed Alireza Javadinia, Sara Shenavaei Zare, Reza Chaman
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Taylor & Francis Group 2025-12-01
الموضوعات:	Esophageal squamous cell carcinoma (ESCC) immune checkpoint inhibitors PD-1 inhibitors immune-related adverse events (irAEs) blood biomarkers neutrophil-to-lymphocyte ratio (NLR)
الوصول للمادة أونلاين:	https://www.tandfonline.com/doi/10.1080/20565623.2025.2527486

مواد مشابهة

Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)—Their Incidence, Management, Multiorgan irAEs, and Rechallenge
حسب: Raju Vaddepally, وآخرون
منشور في: (2022-03-01)

Effects of COVID-19 vaccination on irAEs and prognosis in lung cancer patients receive PD-(L)1 inhibitors
حسب: Ping Luo, وآخرون
منشور في: (2025-12-01)

Editorial: Immune-related adverse Events (irAEs) of biopharmaceuticals
حسب: Alexander Batista-Duharte, وآخرون
منشور في: (2023-05-01)

Peripheral blood markers predict prognosis and irAEs of stage IV driver gene-negative lung adenocarcinoma treated with ICIs
حسب: Yu Li, وآخرون
منشور في: (2025-03-01)

Mapping the genetic–transcriptional landscape of thyroid irAEs in sintilimab therapy: toward biomarker-guided immunotoxicity prediction
حسب: Wei Chen, وآخرون
منشور في: (2025-10-01)

A review of immune checkpoint inhibitor-associated myocarditis: Epidemiology, pathogenesis, and biomarkers
حسب: Le Xu, وآخرون
منشور في: (2025-12-01)

SJS/TEN immune-related dermatologic reaction secondary to immune checkpoint inhibitor pembrolizumab in skin of color
حسب: A.B. Pierre, وآخرون
منشور في: (2023-12-01)

Immune Checkpoint Inhibitors and Lupus Erythematosus
حسب: Hans Vitzthum von Eckstaedt, وآخرون
منشور في: (2024-02-01)

Fever of unknown origin associated with immune checkpoint inhibitors
حسب: Xu Tong, وآخرون
منشور في: (2024-03-01)

A case of coagulation factor V inhibitor induced by immune checkpoint inhibitor therapy
حسب: Yuki Haruta, وآخرون
منشور في: (2024-02-01)

Antiviral therapy can effectively suppress irAEs in HBV positive hepatocellular carcinoma treated with ICIs: validation based on multi machine learning
حسب: Shuxian Pan, وآخرون
منشور في: (2025-01-01)

Impact of steroid dose and timing on efficacy of combination PD-1/CTLA-4 blockade
حسب: Nina B. Curkovic, وآخرون
منشور في: (2025-12-01)

The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosis
حسب: Xiaomin Fu, وآخرون
منشور في: (2025-05-01)

Enhancing Care Through a Virtual Canadian Community of Practice for Managing Immune-Related Adverse Events
حسب: Khashayar Esfahani, وآخرون
منشور في: (2025-02-01)

Post-marketing safety concerns with Tislelizumab: a disproportionality analysis of the FDA adverse event reporting system
حسب: Chen Li, وآخرون
منشور في: (2025-05-01)

The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC
حسب: Ji Li, وآخرون
منشور في: (2022-05-01)

Checkpoint Inhibitor-Induced Colitis—A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options
حسب: Carmen Portenkirchner, وآخرون
منشور في: (2021-04-01)

Correlation between thyroid dysfunction and efficacy of immune checkpoint inhibitors in patients with advanced solid tumors
حسب: Cheng Zhao
منشور في: (2024-11-01)

Checkpoint inhibitor immunotherapy induced inflammatory arthritis secondary to Nivolumab and Ipilimumab: a pediatric first
حسب: John A. Storwick, وآخرون
منشور في: (2024-04-01)

Stage IV renal cell carcinoma achieves pathologic complete response after two ipilimumab plus nivolumab courses despite severe immune-related adverse events: a case report
حسب: Ryo Takada, وآخرون
منشور في: (2024-05-01)

Unravelling the Acute, Chronic and Steroid-Refractory Management of High-Grade Neurological Immune-Related Adverse Events: A Call to Action
حسب: Antonio Malvaso, وآخرون
منشور في: (2024-07-01)

Combining immune-related adverse events and inflammatory profiles enhances prognostic accuracy in metastatic melanoma under PD-1-based therapy
حسب: Dionysios Garmpis, وآخرون
منشور في: (2025-10-01)

Challenges and Limitations of Endocrine Toxicity Evaluation in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy—Retrospective Study from a Tertiary-Level Hospital in Romania
حسب: Simona Coniac, وآخرون
منشور في: (2023-05-01)

Effects of immune checkpoint inhibitor associated endocrinopathies on cancer survival
حسب: Lisa Yang, وآخرون
منشور في: (2024-04-01)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
حسب: Xiaoyan Si, وآخرون
منشور في: (2020-02-01)

Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis
حسب: Hiroyuki Ando, وآخرون
منشور في: (2021-10-01)

Editorial: Autoimmune complications of modern cancer therapies
حسب: Nora Möhn, وآخرون
منشور في: (2024-01-01)

Prognostic value of the combined preoperative plasma fibrinogen and systemic inflammatory indexes in ESCC patients
حسب: Honggang Cao, وآخرون
منشور في: (2023-08-01)

Pembrolizumab‐Induced Severe Pneumonitis in a Patient With Lung Adenocarcinoma After Umbilical Cord Blood Transplantation: A Case Report
حسب: Shunta Yamamoto, وآخرون
منشور في: (2025-08-01)

Nail toxicity with nail bed ulceration associated with pembrolizumab
حسب: Shintaro Maeda, وآخرون
منشور في: (2023-12-01)

JAK Inhibitor Upadacitinib Induces Remission in Refractory Immune‐Related Colitis Triggered by CTLA‐4 and PD‐1 Inhibitor Combination Therapy in Malignant Pleural Mesothelioma: A Case Report
حسب: Masashi Kono, وآخرون
منشور في: (2024-10-01)

Function of 18F-FDG PET/CT radiomics in the detection of checkpoint inhibitor-induced liver injury (CHILI)
حسب: Clémence M. C. Huigen, وآخرون
منشور في: (2025-08-01)

Immune-related thyroid dysfunction as a positive prognostic factor for patients with lung cancer in China: a real-world retrospective study
حسب: Ge Guo, وآخرون
منشور في: (2024-12-01)

Late-Onset Myocarditis Following Immune Checkpoint Inhibitors Therapy: A Case Series with Literature Review
حسب: Harun Muğlu, وآخرون
منشور في: (2025-02-01)

Immune-Related Adverse Events Associated with Atezolizumab: Insights from Real-World Pharmacovigilance Data
حسب: Connor Frey, وآخرون
منشور في: (2024-07-01)

Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis
حسب: Sae Ohwada, وآخرون
منشور في: (2022-06-01)

A case of urticarial vasculitis associated with atezolizumab
حسب: Jade N. Young, BS, وآخرون
منشور في: (2024-01-01)

Pemphigus risk following programmed death receptor-1, programmed death ligand-1, or cytotoxic T-lymphocyte-associated protein 4 inhibitors: A 1:1 propensity-matched, global, retrospective cohort study
حسب: Justin Baroukhian, BA, BS, وآخرون
منشور في: (2025-04-01)

HLA inherence as a potential parameter in checkpoint inhibitor-associated autoimmune adverse event assessment
حسب: Sophia Gandarillas, وآخرون
منشور في: (2024-01-01)

Predicting Objective Response Rate (ORR) in Immune Checkpoint Inhibitor (ICI) Therapies with Machine Learning (ML) by Combining Clinical and Patient-Reported Data
حسب: Sanna Iivanainen, وآخرون
منشور في: (2022-01-01)